# A Real-world Study of Imraldi® Use

> **NCT04089514** · — · COMPLETED · sponsor: **Biogen** · enrollment: 1000 (actual)

## Conditions studied

- Arthritis, Rheumatoid (RA)
- Axial Spondyloarthritis (axSpA)
- Arthritis, Psoriatic (PsA)
- Crohn's Disease (CD)
- Colitis, Ulcerative (UC)

## Interventions

- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT04089514
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-30
- **Primary completion:** 2021-11-30
- **Final completion:** 2021-11-30
- **Target enrollment:** 1000 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04089514

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04089514, "A Real-world Study of Imraldi® Use". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04089514. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*